Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: “MTD” or “ALARA”?
نویسنده
چکیده
Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.
منابع مشابه
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer
BACKGROUND Chemoradiotherapy is the standard treatment for locally advanced non-small cell lung cancer (NSCLC); however, it is disputed whether this treatment is suitable for patients aged ≥75. This study was conducted to determine the maximum tolerated dose (MTD) of pemetrexed for use in concurrent radiotherapy for elderly patients with locally advanced non-squamous NSCLC. METHODS The eligib...
متن کاملConcurrent chemoradiotherapy in locally advanced non-small cell lung cancer: a retrospective analysis of the correlation between radiotherapy-related factors and tumor response
Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...
متن کاملPhase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
INTRODUCTION Although paclitaxel with carboplatin and thoracic radiotherapy has improved survival for patients with locally advanced unresectable non-small cell lung cancer (NSCLC), the optimal dose of paclitaxel has not been well defined in Japan. This study was conducted to determine the maximum tolerated dose (MTD) and recommended dose (RD) of paclitaxel in combination with carboplatin and c...
متن کاملInnovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer.
BACKGROUND While small improvements in outcome have occurred for patients with locally advanced non-small cell lung cancer (NSCLC), 5-year survival results remain low, ranging from 5% to 20%. Distant metastases and local-regional progression remain significant patterns of failure. METHODS Trials investigating innovative treatment strategies for patients with locally advanced and/or unresectab...
متن کاملClinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
BACKGROUND Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS We retrospectively examined 37 patients with locally advanced NSCLC treate...
متن کامل